Helios Technologies (HLIO) Investor presentation summary
Event summary combining transcript, slides, and related documents.
Investor presentation summary
13 Jul, 2026Business overview and strategy
Global leader in motion control and electronic controls, serving diverse end markets with a focus on innovation and diversification.
Operates two main segments: Hydraulics (65% of sales) and Electronics (35% of sales), with a balanced geographic presence in the Americas, EMEA, and APAC.
Growth strategy centers on product innovation, acquisitions, and leveraging centers of excellence for scalable operations.
Maintains a flexible, integrated operating model to drive efficiencies and synergies.
Prioritizes shareholder returns, with a history of quarterly dividends for over 28 years.
Financial performance and outlook
3Q25 sales grew 13% year-over-year to $220M, with full-year 2025 sales outlook of $820M–$830M, up 2–3% from 2024.
Adjusted EBITDA margin for 3Q25 was 20.5%; full-year 2025 margin expected at 19.1–19.4%.
Non-GAAP EPS for 3Q25 was $0.72, up 22% year-over-year; full-year 2025 outlook is $2.43–$2.50, up 16–19%.
Strong cash generation with TTM 3Q25 adjusted free cash flow conversion at 223%.
Focused on shortening the cash conversion cycle and reducing debt while leveraging a strong financial foundation.
Portfolio evolution and product innovation
Transformed through strategic acquisitions, including Enovation Controls, Faster, Balboa Water Group, and others.
2025 saw multiple new product launches across both segments, accelerating innovation pace.
Hydraulics segment serves industrial, agriculture, mobile, and recreational markets; electronics segment strong in health & wellness and industrial applications.
Brands include Sun Hydraulics, Faster, Enovation Controls, Balboa, and others, serving major OEMs and distributors.
Centers of excellence and regional manufacturing support scalable growth and customer proximity.
Latest events from Helios Technologies
- Raised FY2026 outlook after strong Q2 sales, margin gains, and record cash flow.HLIO
Q2 2026 - Imminent ARDS therapy launch in Japan and global phase III trial signal major growth ahead.HLIO
Jefferies Global Healthcare Conference 2026 - Q1 2026 sales up 17% with record margins, cash flow, and a raised full-year outlook.HLIO
Q1 2026 - Director elections, auditor ratification, and equity plan amendment up for shareholder vote.HLIO
Proxy filing - Growth, governance, and sustainability drive key proposals and leadership changes for 2026.HLIO
Proxy filing - Record Q4 and FY25 results, margin gains, and cash flow set up continued growth in FY26.HLIO
Q4 2025 - Sequential margin and cash flow gains offset year-over-year sales declines.HLIO
Q2 2024 - Transformation, margin expansion, and operational resilience drive future growth.HLIO
Baird 2024 Global Industrials Conference - Q1 2025 sales fell 8% YoY, but cash flow, margins, and debt reduction remained strong.HLIO
Q1 2025